Natural killer cells can inhibit the transmission of human cytomegalovirus in cell culture by using mechanisms from innate and adaptive immune responses

Journal of Virology

Volumn 89, Issue 5, 2015, Pages 2906-2917

  Wu, Zeguang ^a   Sinzger, Christian ^a   Reichel, Johanna Julia ^b   Just, Marlies ^a   Mertens, Thomas ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIIA; GAMMA INTERFERON; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CELL CONTACT; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNE EVASION; IMMUNOSURVEILLANCE; INHIBITION KINETICS; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PROTEIN POLYMORPHISM; UL16 GENE; VIRUS ENTRY; VIRUS GENE; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS TRANSMISSION; CYTOMEGALOVIRUS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; SECRETION (PROCESS);

HUMAN HERPESVIRUS 5;

CELLS, CULTURED; CYTOMEGALOVIRUS; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL;

EID: 84923025528     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03489-14     Document Type: Article

References (39)

1. Pass RF. 2001. Cytomegalovirus, p 2675-2705. In Fields BN, Knipe DM, Howley PM, Griffin DE (ed), Fields virology, 4th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Sattentau Q. 2008. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6:815-826. http://dx.doi.org/10.1038/nrmicro1972.
3. Revello MG, Percivalle E, Arbustini E, Pardi R, Sozzani S, Gerna G. 1998. In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest 101:2686-2692. http://dx.doi.org/10.1172/JCI1633.
4. Sinzger C, Knapp J, Plachter B, Schmidt K, Jahn G. 1997. Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J Virol Methods 63:103-112. http://dx.doi.org/10.1016/S0166-0934(97)02082-X.
5. Jost S, Altfeld M. 2013. Control of human viral infections by natural killer cells. Annu Rev Immunol 31:163-194. http://dx.doi.org/10.1146/annurev-immunol-032712-100001.
6. Wu Z, Sinzger C, Frascaroli G, Reichel J, Bayer C, Wang L, Schirmbeck R, Mertens T. 2013. Human cytomegalovirus-induced NKG2Chi CD57hi natural killer cells are effectors dependent on humoral antiviral immunity. J Virol 87:7717-7725. http://dx.doi.org/10.1128/JVI.01096-13.
7. Magri G, Muntasell A, Romo N, Saez-Borderias A, Pende D, Geraghty DE, Hengel H, Angulo A, Moretta A, Lopez-Botet M. 2011. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 117:848-856. http://dx.doi.org/10.1182/blood-2010-08-301374.
8. Biron CA, Byron KS, Sullivan JL. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320:1731-1735. http://dx.doi.org/10.1056/NEJM198906293202605.
9. Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E. 2008. Human NK cells can control CMV infection in the absence of T cells. Blood 112:914-915. http://dx.doi.org/10.1182/blood-2008-05-157354.
10. Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, Retiere C, Sverremark-Ekstrom E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale J, Michaelsson J, Ljunggren HG, Malmberg KJ. 2013. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121:2678-2688. http://dx.doi.org/10.1182/blood-2012-10-459545.
11. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664-3671. http://dx.doi.org/10.1182/blood-2004-05-2058.
12. Sinzger C, Mangin M, Weinstock C, Topp MS, Hebart H, Einsele H, Jahn G. 2007. Effect of serum and CTL on focal growth of human cytomegalovirus. J Clin Virol 38:112-119. http://dx.doi.org/10.1016/j.jcv.2006.11.009.
13. Wu Z, Frascaroli G, Mertens T. 2013. Assessment of natural killer cell responses to human cytomegalovirus-infected macrophages. Methods Mol Biol 1064:289-298. http://dx.doi.org/10.1007/978-1-62703-601-6_21.
14. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. 2008. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 180:6392-6401. http://dx.doi.org/10.4049/jimmunol.180.9.6392.
15. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B. 2008. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89:359-368. http://dx.doi.org/10.1099/vir.0.83286-0.
16. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol 634: 421-430. http://dx.doi.org/10.1007/978-1-60761-652-8_30.
17. Digel M, Sampaio KL, Jahn G, Sinzger C. 2006. Evidence for direct transfer of cytoplasmic material from infected to uninfected cells during cell-associated spread of human cytomegalovirus. J Clin Virol 37:10-20. http://dx.doi.org/10.1016/j.jcv.2006.05.007.
18. Sinzger C, Digel M, Jahn G. 2008. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol 325:63-83. http://dx.doi.org/10.1007/978-3-540-77349-8_4.
19. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, Pandey R, Campbell KS, Orange JS. 2012. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 122:3769-3780. http://dx.doi.org/10.1172/JCI64837.
20. Sainz B, Jr, LaMarca HL, Garry RF, Morris CA. 2005. Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J 2:14. http://dx.doi.org/10.1186/1743-422X-2-14.
21. Yan N, Chen ZJ. 2012. Intrinsic antiviral immunity. Nat Immunol 13: 214-222. http://dx.doi.org/10.1038/ni.2229.
22. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49. http://dx.doi.org/10.1126/science.1198687.
23. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ. 2008. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41:206-212. http://dx.doi.org/10.1016/j.jcv.2007.10.027.
24. Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemcovicova I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA. 2013. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe 13:324-335. http://dx.doi.org/10.1016/j.chom.2013.02.003.
25. Daeron M. 1997. Fc receptor biology. Annu Rev Immunol 15:203-234. http://dx.doi.org/10.1146/annurev.immunol.15.1.203.
26. Ravetch JV, Perussia B. 1989. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell typespecific expression of two genes that differ in single nucleotide substitutions. J Exp Med 170:481-497.
27. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758. http://dx.doi.org/10.1182/blood.V99.3.754.
28. Dargan DJ, Douglas E, Cunningham C, Jamieson F, Stanton RJ, Baluchova K, McSharry BP, Tomasec P, Emery VC, Percivalle E, Sarasini A, Gerna G, Wilkinson GW, Davison AJ. 2010. Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 91:1535-1546. http://dx.doi.org/10.1099/vir.0.018994-0.
29. Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW. 2010. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120:3191-3208. http://dx.doi.org/10.1172/JCI42955.
30. Katze MG, He Y, Gale M, Jr. 2002. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:675-687. http://dx.doi.org/10.1038/nri888.
31. Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD. 1999. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J Immunol 162:6107-6113.
32. Benedict CA, Banks TA, Senderowicz L, Ko M, Britt WJ, Angulo A, Ghazal P, Ware CF. 2001. Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus detente. Immunity 15:617-626. http://dx.doi.org/10.1016/S1074-7613(01)00222-9.
33. Iversen AC, Norris PS, Ware CF, Benedict CA. 2005. Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. J Immunol 175:7568-7574. http://dx.doi.org/10.4049/jimmunol.175.11.7568.
34. Pak-Wittel MA, Yang L, Sojka DK, Rivenbark JG, Yokoyama WM. 2013. Interferon-gamma mediates chemokine-dependent recruitment of natural killer cells during viral infection. Proc Natl Acad Sci USA 110: E50-E59. http://dx.doi.org/10.1073/pnas.1220456110.
35. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E, Porgador A, Honigman A, Plachter B, Mevorach D, Wolf DG, Mandelboim O. 2005. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6:515-523. http://dx.doi.org/10.1038/ni1190.
36. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. 2012. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86:7444-7447. http://dx.doi.org/10.1128/JVI.00467-12.
37. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, Campanini G, Gallina A, Baldanti F, Revello MG. 2008. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89:853-865. http://dx.doi.org/10.1099/vir.0.83523-0.
38. Frenzel K, Ganepola S, Michel D, Thiel E, Kruger DH, Uharek L, Hofmann J. 2012. Antiviral function and efficacy of polyvalent immunoglobulin products againstCMVisolates in different human cell lines. Med Microbiol Immunol 201:277-286. http://dx.doi.org/10.1007/s00430-012-0229-2.
39. Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M. 2011. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 48:1512-1517. http://dx.doi.org/10.1016/j.molimm.2011.04.010.